


PRODUCT INFORMATION



Radotinib

Item No. 19923

CAS Registry No.: 926037-48-1
Formal Name: 4-methyl-N-[3-(4-methyl-1H-imidazol-1-yl)-5-(trifluoromethyl)phenyl]-3-[[4-(2-pyrazinyl)-2-pyrimidinyl]amino]-benzamide
Synonym: IY-5511
MF: C₂₇H₂₁F₃N₈O
FW: 530.5
Purity: ≥98%
UV/Vis.: λ_{max}: 215, 270 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Radotinib is supplied as a crystalline solid. A stock solution may be made by dissolving the radotinib in the solvent of choice. Radotinib is soluble in organic solvents such as DMSO and dimethyl formamide, which should be purged with an inert gas. The solubility of radotinib in these solvents is approximately 10 and 3 mg/ml, respectively.

Description

Radotinib is a selective second generation tyrosine kinase inhibitor that targets both the wild-type and mutant forms of Bcr-Abl, with an IC₅₀ value of 30.6 nM in Ba/F3 human chronic myeloid leukemia cells expressing the wild-type form.¹ Radotinib also inhibits platelet-derived growth factor receptors (PDGFRs) α and β with IC₅₀ values of 75.5 and 130 nM, respectively.^{2,3} Binding of radotinib to Bcr-Abl *in vitro* inhibits the phosphorylation of the downstream signaling mediator CrkL.³ In acute myeloid leukemia cells, *in vitro* treatment with radotinib at doses of 10-100 μM reduces viability, activates the mitochondrial apoptosis pathway, and promotes expression of the differentiation marker CD11b.²

References

1. Zabriskie, M.S., Vellore, N.A., Gantz, K.C., *et al.* Radotinib is an effective inhibitor of native and kinase domain-mutant BCR-ABL1. *Leukemia* **29(9)**, 1939-1942 (2015).
2. Heo, S.-K., Noh, E.-K., Yoon, D.-J., *et al.* Radotinib induces apoptosis of CD11b⁺ cells differentiated from acute myeloid leukemia cells. *PLoS One* **10(6)**, e0129853 (2015).
3. Kim, S.-H., Menon, H., Jootar, S., *et al.* Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. *Haematologica* **99(7)**, 1191-1196 (2014).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/22/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM